Complix

Technologiepark 94

9052 Zwijnaarde

BE

Complix

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Upcoming events

Latest news

  • Celyad Oncology appoints Georges Rawadi as its new CEO

    Tuesday March 28th 2023

  • BioLizard appoints Paul Vauterin as Chief Technology Officer

    Monday March 27th 2023

  • ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI

    Monday March 27th 2023